Using Nivolumab with or without Relatlimab for Treating Resectable Liver Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of administering Nivolumab, an immunotherapy drug, either alone or in combination with Relatlimab, to patients with potentially resectable hepatocellular carcinoma (HCC). The approach involves neoadjuvant and adjuvant treatment phases to assess how well these therapies can be tolerated and their impact on tumor response before and after surgery. Patients will be closely monitored for safety and efficacy outcomes throughout the treatment process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

• Technically resectable HCC as defined by:

* HCC may be diagnosed pathologically, or noninvasively by the American Association for the Study of Liver Diseases (AASLD) criteria or the Organ Procurement and Transplant Network (OPTN) Obligatory Diagnostic Criteria for Hepatocellular Carcinoma (HCC).

No extrahepatic spread, no nodal disease, and no bilateral left and right branch portal vein involvement.

* Measurable disease per RECIST 1.1 as determined by the investigator.
* Age ≥ 18 years old on the day of consent.
* ECOG performance status ≤1 or Karnofsky ≥80.
* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
* Patients must have adequate liver remnant and function.
* Antiviral therapy per local standard of care for hepatitis B.
* LVEF assessment with documented LVEF ≥ 50% by either TTE or MUGA (TTE preferred) within 6 months from first study drug administration.
* Woman of child-bearing potential must have a negative pregnancy test.
* Must use acceptable form of birth control while on study.
* Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

* Fibrolamellar carcinoma or mixed HCC.
* Receiving, or previously received, any systemic chemotherapy, or investigational agent for HCC.
* Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies.
* Has a known additional malignancy that is expected to require active treatment within two years, or is likely to be life-limiting in the opinion of the treating investigator. Superficial bladder cancer, non-melanoma skin cancers, or low grade prostate cancer not requiring therapy would not exclude participation in this trial.
* History of HIV infection.
* Active co-infection with HBV and HDV.
* Has a diagnosis of immunodeficiency, or is receiving systemic steroid therapy.
* Prior tissue or organ allograft or allogeneic bone marrow transplantation.
* History of any autoimmune disease requiring systemic treatment within the past 2 years.
* Systemic or topical corticosteroids at immunosuppressive doses (\> 10 mg/day of prednisone or equivalent).
* Confirmed history of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.
* Uncontrolled intercurrent illness.•
* Uncontrolled or significant cardiovascular disease.
* Significant heart disease.
* Moderate or severe ascites.
* Known or suspected hypersensitivity to study treatment.
* Are pregnant or breastfeeding.
* WOCBP and men with female partners (WOCBP) who are not willing to use contraception.
* Unable to have blood drawn.
* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
* Any illicit drugs or other substance abuse.

Where it's running

• Sidney Kimmel Comprehensive Cancer Center
  Baltimore, Maryland, United States Recruiting
• The Ohio State University, Wexner Medical Center
  Columbus, Ohio, United States Recruiting

Study contacts

• Principal investigator: Mark Yarchoan, MD — SKCCC Johns Hopkins Medical Institution
• Study coordinator: Colleen Apostal, RN
• Email: GIClinicalTrials@jhmi.edu
• Phone: 410-614-3644

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• HEPZATO KIT with Opdualag for metastatic melanoma that has spread to the liver

  This will try adding HEPZATO KIT to Opdualag (nivolumab + relatlimab) to see if it's safe and helps people with metastatic melanoma that has spread to the liver.

  Recruiting Phase 1/2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07281924

• Comparing two immunotherapy combinations and their immune effects in unresectable or metastatic melanoma

  This will test whether two different first-line immunotherapy combinations produce different immune responses in tumors and blood of people with unresectable or metastatic melanoma.

  Recruiting University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07223411

• Neoadjuvant ipilimumab, relatlimab, and nivolumab combinations for resectable cutaneous and mucosal melanoma

  This phase 2 trial will test several immunotherapy combinations given before surgery to try to reduce recurrence in adults with resectable stage 3 cutaneous melanoma or resectable mucosal melanoma, including patients predicted or known to respond poorly to standard anti‑PD‑1 therapy.

  Recruiting Phase 2 Melanoma Institute Australia · Wollstonecraft, New South Wales · NCT06999980

• Sacituzumab govitecan with nivolumab, with or without relatlimab, for metastatic triple-negative breast cancer

  This trial tests whether adding nivolumab alone or nivolumab plus relatlimab to sacituzumab govitecan helps people with metastatic triple-negative breast cancer who have had one prior line of chemotherapy.

  Recruiting Phase 1/2 Yale University · New Haven, Connecticut · NCT06963905

• Nivolumab with or without relatlimab for newly diagnosed IDH‑wildtype glioblastoma

  This trial will test whether giving nivolumab alone or together with relatlimab around surgery helps adults with newly diagnosed IDH‑wildtype glioblastoma.

  Recruiting at 4 sites Phase 2 Duke University · New York, New York and 3 other locations · NCT06816927

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.